EUVIMEDEUVIMED entdecken
Crossref

Quality by design enabled formulation development of regorafenib monohydrate loaded PEGylated PLGA polymeric nanoparticles: Enhanced oral bioavailability and biopharmaceutical attributes

Dhananjay Panigrahi, Suryakanta Swain, Pratap Sahu, Debashish Ghose, Bikash Ranjan Jena

Nanomedicine Journal · 2024-10 · 11 (4) · 401-416

DOI: 10.22038/nmj.2024.76842.1867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Journal, 2024-10. Verfasst von Dhananjay Panigrahi und 4 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective(s): Using a quality-by-design methodology, the current research is aimed to prepare and enhance the PEGylated PLGA-loaded regorafenib monohydrate polymeric nanoparticles for enhancing oral bioavailability and biopharmaceutical attributes. The oral multi-kinase inhibitor inhibits VEGFR2-TIE2 tyrosine kinases on two separate targets, which results in anti-angiogenic activity. It also inhibits stromal and oncogenic receptor tyrosine kinases. Materials and Methods: The current study developed nanosized, biocompatible, and PEGylated PLGA polymeric nanoparticles to administer regorafenib monohydrate to patients with metastatic colon cancer. This was accomplished using a modified nanoprecipitation technique to make drug-encapsulated PEGylated PLGA nanoparticles with poloxamer 188 as a stabilizer.

Results

The polymeric nanoformulations were characterized for zeta potential, distribution of particle size, entrapment efficiency, DSC, FT-IR, X-RD, and SEM. Both in vitro and in vivo experimental studies were performed for the pure drug and the improved nanoparticle formulation.

Conclusion

The nanoparticles obtained from optimization studies were found to have smaller particle sizes, higher entrapment efficiency (%), drug loading capacity, spherical shape particles, amorphous drug embedded matrix, and a biphasic delayed release pattern. These findings suggest that drug-loaded PEGylated PLGA nanoparticles are a potent formulation for the treatment of colon cancer, with improved oral bioavailability and biopharmaceutical properties.

Schlagwörter

bioavailability potentialpolymeric nanoparticlesquality by designregorafenib monohydratezeta potential

Zitieren

APA

Panigrahi, D., Swain, S., Sahu, P., Ghose, D., & Jena, B. R. (2024). Quality by design enabled formulation development of regorafenib monohydrate loaded PEGylated PLGA polymeric nanoparticles: Enhanced oral bioavailability and biopharmaceutical attributes. Nanomedicine Journal, 11(4), 401-416. https://doi.org/10.22038/nmj.2024.76842.1867

Vancouver

Panigrahi D, Swain S, Sahu P, Ghose D, Jena BR. Quality by design enabled formulation development of regorafenib monohydrate loaded PEGylated PLGA polymeric nanoparticles: Enhanced oral bioavailability and biopharmaceutical attributes. Nanomedicine Journal. 2024;11(4):401-416. doi:10.22038/nmj.2024.76842.1867

BibTeX
@article{Panigrahi2024,
  author = {Panigrahi, Dhananjay and Swain, Suryakanta and Sahu, Pratap and Ghose, Debashish and Jena, Bikash Ranjan},
  title = {Quality by design enabled formulation development of regorafenib monohydrate loaded PEGylated PLGA polymeric nanoparticles: Enhanced oral bioavailability and biopharmaceutical attributes},
  journal = {Nanomedicine Journal},
  year = {2024},
  volume = {11},
  number = {4},
  pages = {401--416},
  doi = {10.22038/nmj.2024.76842.1867}
}
Kostenlos starten →